This study is looking at how well High Intensity Focused Ultrasound (HIFU) works for treating prostate cancer. HIFU uses focused sound waves to target and destroy diseased prostate tissue, while trying to preserve healthy areas. The Sonablate HIFU device, which was approved by the FDA in 2015, will be used. Researchers will collect information from your medical records and ask you to fill out questionnaires about your health and quality of life. To join, you must be a man between 40 and 85 years old, have a PSA (prostate-specific antigen) level of 20 or less, and have a prostate volume of 70 cc or less. You must have already chosen or undergone HIFU as your treatment. The main goal is to see how well the treatment controls the cancer after 6 months. The current status of this study is unclear.

Study design

This is an observational study involving up to 100 male participants. It collects data from medical records and questionnaires.

What's involved

You will have already undergone or opted to receive the HIFU procedure as part of your standard care. The study involves reviewing your medical records and completing questionnaires.

Compensation

Not stated in the trial record.

Follow-up

The study measures oncological response at 6 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.